Protagonist Therapeutics Inc
|Market Cap (Intraday)||1.47B|
|2yr Forward PE||N/A|
Protagonist Therapeutics Inc Stock, NASDAQ:PTGX
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.